【4.4】2011年氟康唑预防隐球菌病.pdfVIP

Articles Primary prophylaxis of cryptococcal disease with ? uconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Rosalind Parkes-Ratanshi, Katie Wakeham, Jonathan Levin, Deodata Namusoke, James Whitworth, Alex Coutinho, Nathan Kenya Mugisha, Heiner Grosskurth, Anatoli Kamali, David G Lalloo, on behalf of the Cryptococcal Trial Team Summary Background Cryptococcal disease remains an important cause of morbidity and mortality in HIV-infected individuals Lancet Infect Dis 2011; in sub-Saharan Africa, despite the intro duction of antiretroviral therapy. We studied ? uconazole as primary prophylaxis 11: 933–41 against cryptococcal disease in patients awaiting or starting antiretroviral therapy in Uganda. Published Online October 7, 2011 DOI:10.1016/S1473- Methods In this prospective, double-blind randomised controlled trial, we enrolled HIV-positive adults with CD4 3099(11)70245-6 counts less than 200 cells per μL, cryptococcal antigen (CrAg)-negative, naive for antiretroviral therapy, and coming See Comment page 892 from ? ve local AIDS organisations in Masaka district, Uganda. Enrolment took place between Sept 14, 2004, and Medical Research Council Feb 1, 2008. Participants were randomly allocated to placebo or 200 mg ? uconazole three times per week (1:1) in (MRC)/Uganda Virus Research blocks of 40. Randomisation was done with ralloc procedure in Stata. Participants were reviewed after 4 weeks and Institute (UVRI) Uganda referred for antiretroviral therapy, then seen every 8 weeks. Participants discontinued trial treatment when CD4 Research Unit on AIDS, UVRI,